Feature Channels: Immunology

• share
• favorite_border

Two complementary studies show that defibrotide can successfully suppress the formation and progression of neutrophil extracellular traps, or NETs, which are web-like networks of toxic proteins that play a role in forming blood clots and promoting inflammation in several disease, including COVID-19. Researchers say findings may set the stage for defibrotide clinical trials in potentially several diseases.

• share
• favorite_border

Immune cells could be doing much more than we think in protecting our eyes – Jefferson researchers uncover new details.

• share
• favorite_border

Beyond Delta and Omicron: Plant-Based Nutrition for Whole-Body Health in the Age of COVID

• share
• favorite_border

A combination of vaccination and naturally acquired infection appears to boost the production of maximally potent antibodies against the COVID-19 virus, new UCLA research finds.

• share
• favorite_border

The study, called COVID CommUNITY- First Nations, will collect, analyze, and report data relating to COVID-19 vaccine effectiveness and safety, as well as explore hesitancy in three First Nations communities in Canada: Six Nations of the Grand River in southwestern Ontario; Lac La Ronge Indian Band in Saskatchewan; and Wendake in Quebec.

• share
• favorite_border

Among HIV-positive black and Latino men who have sex with men, the use of methamphetamine combined with intimate partner violence may increase the risk for developing chronic diseases such as cardiovascular disease and other disorders.

• share
• favorite_border

Scientists at the Sbarro Institute for Cancer Research and Molecular Medicine, Center of Biotechnology, located at Temple University’s College of Science and Technology, working with collaborators in Italy, have described the age-related differences in inflammatory response to an emerging immunotherapy treatment for Non-Small-Cell Lung Cancer (NSCLC) called PD-1 blockade.

• share
• favorite_border

Scientists at La Jolla Institute for Immunology (LJI) and Massachusetts Institute of Technology (MIT), have found a possible way to improve the effectiveness of COVID-19 vaccines—and any vaccine.

• share
• favorite_border

Patients whose immune systems are weakened due to cancer, organ or bone marrow transplants, chronic diseases, or the medications used to treat these conditions may feel like they have enough on their plates without worrying about whether and when they should take an additional dose of COVID-19 vaccine and a flu shot.

• share
• favorite_border

Scientists at The Wistar Institute have identified two genes that play a critical role in protecting ovarian cancer from the immune system.

• share
• favorite_border

High levels of European ancestry are associated with an increase in type I interferon pathway activity in early infection

• share
• favorite_border

A new article published in The New England Journal of Medicine suggests that secondary antibodies known as “anti-idiotype antibodies” could be responsible for some of the side effects of COVID-19 vaccines and the symptoms of long-haul COVID.

• share
• favorite_border

In a collaborative study, Cleveland Clinic researchers sought to understand how COVID-19 infection affects pregnant mothers and their children. They published the results of their clinical study in Cell Reports Medicine.

• share
• favorite_border

Researchers discovered that antihistamines are associated with improved responses to immunotherapy. Their work revealed a role for the histamine receptor in suppressing T cell activation to block anti-tumor immune responses.

• share
• favorite_border

A vaccine booster is readied for use.

• share
• favorite_border

About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as patches of red, inflamed skin and painful, scaly rashes. Although there are effective treatments for psoriasis, not everyone responds to these therapies—and for many, the relief is temporary.

• share
• favorite_border

People taking TNF inhibitors, a kind of immunosuppressive drug used to treat rheumatoid arthritis and other autoimmune conditions, produced a weaker and shorter-lived antibody response after two doses of Pfizer's COVID-19 vaccine, according to a study from Washington University School of Medicine in St. Louis. A third vaccine dose drove antibody levels back up, indicating that this additional dose may provide protection as the virus's delta variant continues to spread.